| Biologic Therapy |
0 |
0.9 |
| Colorectal Cancer |
0 |
0.96 |
| Lung Cancer |
0 |
0.96 |
| Non-Small Cell Lung Cancer |
0 |
0.81 |
| Breast Cancer |
0 |
0.73 |
| Cancer |
0 |
1 |
| Antineoplastic Drug |
0 |
0.63 |
| Head and Neck Cancer |
0 |
0.58 |
| Advanced and Metastatic Breast Cancer |
0 |
0.57 |
| Triple Negative Breast Cancer |
0 |
0.56 |
| Metastasis |
0 |
0.54 |
| Colon Cancer |
0 |
0.53 |
| Small Cell Lung Cancer |
0 |
0.48 |
| Genomic Medicine |
0 |
0.46 |
| Toxicology |
0 |
0.46 |
| Humanized Monoclonal Antibody |
0 |
0.31 |
| Chemotherapy |
0 |
0.26 |
| Breast |
0 |
0.22 |
| KRAS |
0 |
0.22 |
| Tumor |
0 |
0.22 |
| Multiple Myeloma |
0 |
0.2 |
| Brain Metastasis |
0 |
0.19 |
| Angiogenesis Inhibitors |
0 |
0.17 |
| Immunotherapy |
0 |
0.17 |
| Neoadjuvant Therapy |
0 |
0.16 |
| Epidermal Growth Factor Receptor |
0 |
0.11 |
| Hormonal Therapy |
0 |
0.09 |
| Hospital |
0 |
0.09 |
| Immunomodulator |
0 |
0.09 |
| Interstitial Lung Disease |
0 |
0.09 |
| Lung |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Stem Cell Research and Therapy |
0 |
0.08 |
| Biomarker |
0 |
0.04 |
| BRAF |
0 |
0.04 |
| Brain |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Melanoma |
0 |
0.04 |
| Nausea |
0 |
0.04 |
| New York |
0 |
0.04 |
| Proteasome Inhibitor |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Resection |
0 |
0.04 |
| Surgery |
0 |
0.04 |
| Taxane |
0 |
0.04 |
| Transplantation |
0 |
0.04 |
| White Blood Cell Count |
0 |
0.04 |